Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CLYM vs KTTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Captures Overall Composite Edge (43.7 HOLD vs 42.1 HOLD), While KTTA Leads 2–1 on Growth & Valuation Pillars

CLYM Overall Winner 6-Pillar Tally: CLYM 1 – 2 KTTA (3 Tie) Matrix Metrics: CLYM 5 – 1 KTTA

As of Nov 20, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (43.7/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 5–1 (led by Balance Sheet & Cash Flow), while KTTA wins 2–1 across the 6-pillar growth and valuation breakdown. CLYM trades at $9.19 (N/M Forward P/E, 0.0% operating margin) versus KTTA at $0.48 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. KTTA 42.1/100 HOLD) and 1.42β · 106% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLYM vs KTTA
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.19
-0.97% 1D
Market Cap $545.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.42β · 106% Vol
Unified Composite Score
43.7 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.4%), weak momentum, RSI 41
RSI-14: 40.6 · SMA20: $10.04 · SMA50: $11.01
KTTA NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
TTM Revenue $486,559
Forward P/E N/M
Beta / 30D Vol 0.68β · 185% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.1%) with fading momentum, RSI 50
RSI-14: 49.6 · SMA20: $0.48 · SMA50: $0.47

6-Pillar Scorecard Institutional Category Breakdown (CLYM 1 – 2 KTTA)

Columns: Metric · CLYM · KTTA
1. Valuation Multiples KTTA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 36.3x
2. Growth & Scale KTTA
Revenue Growth (YoY) +0.0% +1498.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $486,559
Market Cap $545.1M $17.7M
3. Profitability & Quality Tie
Gross Margin N/A -0.5%
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -29.3% -88.8%
4. Balance Sheet & Cash Flow CLYM
Cash Generation (TTM) N/A -$18M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.95 Book/Sh · -29.3% ROE $1.31 Book/Sh · -88.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLYM (5) vs KTTA (1)
Institutional Metric CLYM KTTA Criterion Row Edge
Market Capitalization
Scale
$545.1M $17.7M Larger Scale CLYM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +1498.1% Higher Growth KTTA
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-29.3% -88.8% Higher ROE CLYM
52-Week Range Position
Momentum
45% ($2–$18) 11% ($0–$2) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
1.42β · 106% Vol 0.68β · 185% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
43.7 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite CLYM
Trailing 12M Revenue (USD)
Operating Scale
N/A $486,559 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -0.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 36.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($3.95 Book/Sh · -29.3% ROE) -$18M ($1.31 Book/Sh · -88.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KTTA +20.33 pp
CLYM: -12.81% · KTTA: +7.52%
3M Horizon KTTA +38.75 pp
CLYM: -43.96% · KTTA: -5.21%
6M Horizon CLYM +15.14 pp
CLYM: -16.45% · KTTA: -31.59%
1Y Horizon CLYM +398.87 pp
CLYM: +399.46% · KTTA: +0.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs KTTA. Trailing 12-month operating profitability (CLYM 0.0% vs KTTA 0.0%) and valuation multiples (CLYM N/M vs KTTA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M
KTTA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$486,559
Gross Margin-0.5%
Op. Margin0.0%
ROE / Fwd P/E-88.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KTTA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $545.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
KTTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $17.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLYM vs KTTA Key Questions & Quantitative Answers

As of Nov 20, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Pasithea Therapeutics Corp. (KTTA) on higher Unified Composite conviction (43.7/100 HOLD vs. 42.1/100 HOLD) after splitting the core matrix 5–1 (led by Balance Sheet & Cash Flow), while KTTA wins 2–1 across the 6-pillar growth and valuation breakdown. CLYM trades at $9.19 (N/M Forward P/E, 0.0% operating margin) versus KTTA at $0.48 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: CLYM earns the overall head-to-head edge with a stronger Unified Composite Score (43.7/100 HOLD vs. KTTA 42.1/100 HOLD) and 1.42β · 106% Vol risk profile, whereas KTTA leads top-line expansion (+1498.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KTTA leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with KTTA at +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus $486,559 for KTTA. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KTTA.

KTTA screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus KTTA (-88.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 106% Vol realized risk). By comparison, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.